In the other 16 day trial, CA treatment also reduced TNF-α activation, suggest an anti-RA effect via attenuation of cytokines, chemokines, osteoclastogenic factors, transcription factors, and mitogen-activated protein kinase (MAPK). The gene discussed is WNK2; the disease is rheumatoid arthritis.